{"id":"recombinant-asparaginase","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Coagulopathy"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Neurotoxicity"}]},"_chembl":{"chemblId":"CHEMBL2108989","moleculeType":"Enzyme"},"_dailymed":{"setId":"857e53aa-1098-4dad-b654-0276cdd43e03","title":"RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN) INJECTION [JAZZ PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Leukemic blasts, particularly in acute lymphoblastic leukemia (ALL), often cannot synthesize their own asparagine and depend on exogenous sources. By depleting circulating asparagine, the enzyme selectively inhibits protein synthesis in these malignant cells while normal cells can synthesize asparagine endogenously, creating a therapeutic window.","oneSentence":"Recombinant asparaginase depletes the amino acid asparagine from the bloodstream, starving asparagine-dependent leukemic cells of an essential nutrient required for protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:26.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Acute myeloid leukemia (AML)"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT07133997","phase":"PHASE1","title":"Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":26},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02981628","phase":"PHASE2","title":"Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-06-19","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT06600659","phase":"","title":"A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-02","conditions":"Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia","enrollment":10},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT00590915","phase":"","title":"Erwinase Master Treatment Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"Phoenix Children's Hospital","startDate":"","conditions":"Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia","enrollment":""},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT03156790","phase":"PHASE2","title":"PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2019-04-26","conditions":"Acute B-Cell Lymphoblastic Leukaemia","enrollment":40},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":"Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome","enrollment":280},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT02393859","phase":"PHASE3","title":"Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-10","conditions":"Leukemia, Acute Lymphoblastic","enrollment":111},{"nctId":"NCT04145531","phase":"PHASE2, PHASE3","title":"An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-12-27","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia","enrollment":229},{"nctId":"NCT05780294","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-04-01","conditions":"Nasopharyngeal Carcinoma, Leucogen, Chemotherapy","enrollment":132},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT04326439","phase":"PHASE2","title":"AflacLL1901 (CHOA-AML)","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-24","conditions":"Acute Myeloid Leukemia, AML, Childhood","enrollment":8},{"nctId":"NCT04943952","phase":"","title":"JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase","status":"APPROVED_FOR_MARKETING","sponsor":"Jazz Pharmaceuticals","startDate":"","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT01643408","phase":"PHASE2","title":"A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2012-11","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":30},{"nctId":"NCT00439296","phase":"PHASE1, PHASE2","title":"ABT-751 With Chemotherapy for Relapsed Pediatric ALL","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2006-05-22","conditions":"Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia","enrollment":9},{"nctId":"NCT00137111","phase":"PHASE3","title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2000-07-08","conditions":"Lymphoblastic Leukemia, Acute","enrollment":501},{"nctId":"NCT00720109","phase":"PHASE2, PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":63},{"nctId":"NCT00928200","phase":"PHASE1","title":"Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-04-13","conditions":"Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase","enrollment":1},{"nctId":"NCT02718755","phase":"PHASE2","title":"Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05","conditions":"Hematologic Malignancy","enrollment":""},{"nctId":"NCT02283190","phase":"PHASE1","title":"1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Ashkan Emadi","startDate":"2014-04","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT02419755","phase":"PHASE2","title":"Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-04-14","conditions":"Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia","enrollment":12},{"nctId":"NCT00186875","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2003-11","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic","enrollment":47},{"nctId":"NCT02647190","phase":"PHASE1","title":"Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-01","conditions":"Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older","enrollment":""},{"nctId":"NCT00002744","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-05","conditions":"Leukemia","enrollment":1970},{"nctId":"NCT02150928","phase":"PHASE2","title":"An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2014-05","conditions":"Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)","enrollment":""},{"nctId":"NCT00506597","phase":"NA","title":"Erwinase Study in Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-05","conditions":"Leukemia","enrollment":33},{"nctId":"NCT01251809","phase":"PHASE1, PHASE2","title":"Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia","status":"TERMINATED","sponsor":"medac GmbH","startDate":"2011-01","conditions":"Acute Lymphoblastic Leukaemia","enrollment":56},{"nctId":"NCT00784017","phase":"PHASE3","title":"Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2008-10","conditions":"Acute Lymphoblastic Leukemia","enrollment":199},{"nctId":"NCT00002798","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-08","conditions":"Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a)","enrollment":880},{"nctId":"NCT00983138","phase":"PHASE2","title":"Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2009-07","conditions":"Acute Lymphoid Leukemia","enrollment":12},{"nctId":"NCT00187083","phase":"PHASE3","title":"A Study of Children With Refractory or Relapsed ALL","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"1997-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"recombinant asparaginase","genericName":"recombinant asparaginase","companyName":"medac GmbH","companyId":"medac-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant asparaginase is used to treat various types of leukemia, including Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, as well as Down Syndrome. It works by hydrolyzing the amino acid asparagine, which is essential for the growth and survival of certain cancer cells.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}